Gilead Sciences (GILD) Tops Q4 EPS by 1c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities
February 11, 2026 8:36 AM ESTBofA Securities analyst Tim Anderson raised the price target on Gilead Sciences (NASDAQ: GILD) to $162.00 (from $154.00) while maintaining a Buy rating.
The analyst comments "GILD reported strong 4Q product revenues of $7.9bn ahead of Street estimates (BofA: +4%, cons: +4%) driven by demand outperformance from... More
